|
Orthologous residues
|
|
eIF6 (human): S235‑p, eIF6 (mouse): S235‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
COS (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
monkey
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKCA (human)
|
pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
translation, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Other
|
|
Disrupts
|
molecular association, regulation
|
translation, altered
|
electrophoretic visualization, in vitro
|
|
|
Comments:
release from 60S ribosomal subunit
|
